I
Inmagene Biopharmaceuticals
Inmagene is a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases
About Inmagene Biopharmaceuticals
Inmagene Biopharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for autoimmune diseases. The company operates in the global healthcare market, targeting a range of autoimmune conditions that affect millions of patients worldwide. Inmagene's business model revolves around research and development (R&D) of new drugs, with a focus on cost-efficient innovation to bring effective therapies to market. The company generates revenue through the commercialization of its proprietary drugs, as well as through partnerships and licensing agreements with other pharmaceutical companies. Inmagene serves a diverse client base, including healthcare providers, hospitals, and patients in need of advanced treatment options for autoimmune diseases. The company has secured significant funding, including a $21 million Series B financing round, to support its R&D efforts and expand its market presence. Inmagene's strategic locations in Hangzhou, Shanghai, and San Diego enable it to leverage global expertise and resources in the biopharmaceutical industry.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 47
- Open positions
- 1
- Dealroom signal
- 82.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Dec 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Apr 2026 | $30M | — | OrbiMed · Coastlands Capital · OmegaFunds · Trails Edge Capital Partners | ↗ |
| IPOOther financing | Dec 2024 | $0 | — | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Inmagene Biopharmaceuticals is 2.8K monthly website visits, down 68.2% over the last three months. Inmagene Biopharmaceuticals's team declined 6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Inmagene Biopharmaceuticals in the San Diego ecosystem
The Inmagene Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Vertex Ventures China
South China Venture Capital
Kunlun Capital
Panacea Venture
Series B and later5 investors entered at this stage
Highlight Capital- KFKunlun Fund
TMT Investments- TCTriWise Capital
VMS Group
Other known investors4 additional known investors
- CCCoastlands Capital
OmegaFunds
OrbiMed- TPTrails Edge Capital Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Inmagene Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Inmagene Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










